Emmanuel Ewara

Canadian patients want faster access to innovative therapies, while public and private payers face growing pressure to ensure long-term system sustainability. From high-cost gene therapies to treatments for rare diseases, traditional reimbursement models are being tested like never before.

Drug contracting has emerged as a key tool to bridge these competing needs – but how do we ensure contracts enable timely access and innovation instead of creating new barriers?

• Gain unique perspectives from both high-volume biologics and rare disease medicines.
• Explore how contracting in Canada can be streamlined, the role of value-based agreements that link payment to real-world outcomes
• Hear strategies to build sustainable access to today’s medicines and the therapies of tomorrow.